You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 243 No. 24, June 27, 1980 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (28)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Guillain-Barré Syndrome in Recipients of A/New Jersey Influenza Vaccine

James S. Marks, MD; Thomas J. Halpin, MD, MPH

JAMA. 1980;243(24):2490-2494.


Abstract

In late 1976, when 32% of the eligible population of Ohio received the A/New Jersey influenza (swine flu) vaccine, systematic contact of neurologists was used to evaluate the possible association of Guillain-Barré syndrome (GBS) with receipt of the vaccine. The overall rate of GBS was significantly higher among vaccine recipients (13.3/106) than in nonrecipients (2.6/106). Peak time of onset was two to three weeks after receiving the vaccine, and cases among vaccinees were less likely to have a history of antecedent infection than were cases in unvaccinated persons. Even when the effect of one highly associated vaccine lot was removed, an elevated risk of GBS remained in vaccinees regardless of manufacturer or vaccine type (bivalent or monovalent). Systematic surveillance is needed for rare serious reactions from all vaccines.

(JAMA 243:2490-2494, 1980)



Author Affiliations

From the Field Services Division, Bureau of Epidemiology, Center for Disease Control, Atlanta (Dr Marks), and the Bureau of Preventive Medicine, Ohio Department of Health, Columbus (Dr Halpin). Dr Marks is now with the Robert Wood Johnson Clinical Scholar Program, Yale University, New Haven, Conn.


Footnotes

Reprint requests to Ohio Department of Health, PO Box 118, Columbus, OH 43216 (Dr Halpin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Historical Perspective -- Emergence of Influenza A (H1N1) Viruses
Zimmer and Burke
NEJM 2009;361:279-285.
FULL TEXT  

Implications of the Emergence of a Novel H1 Influenza Virus
Belshe
NEJM 2009;360:2667-2668.
FULL TEXT  

Re-emerging infections: Part 4: Respiratory infections
Mayon-White
British Journal of Infection Control 2005;6:13-15.
ABSTRACT  

Guillain-Barre Syndrome Following Influenza Vaccination
Haber et al.
JAMA 2004;292:2478-2481.
ABSTRACT | FULL TEXT  

The Swine Flu Vaccine and Guillain-BarrE Syndrome: A Case Study in Relative Risk and Specific Causation
Freedman and Stark
Eval Rev 1999;23:619-647.
ABSTRACT  

The Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 Influenza Vaccines
Lasky et al.
NEJM 1998;339:1797-1802.
ABSTRACT | FULL TEXT  

Swine Influenza Vaccine and Guillain-Barre Syndrome: Epidemic or Artifact?
Kurland et al.
Arch Neurol 1985;42:1089-1090.
ABSTRACT  

Acute Inflammatory Polyradiculoneuropathy Following Hymenoptera Stings
Bachman et al.
JAMA 1982;247:1443-1445.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1980 American Medical Association. All Rights Reserved.